NCT01593332

Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Mashhad University of Medical Sciences · Academic / Other
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In this project the investigators decide to evaluate the efficacy and safety of half dose mabthera (it means 500 mg infusion two weeks apart) in conventional drug resistant cases of rheumatoid arthritis. The investigators choose this drug because the use of anti-TNF drugs limited in the investigators refractory patients as the first line drugs because of its cost.

Conditions

• DMARD Resistant Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	Rituximab	two 500 mg rituximab infusions 2 weeks apart
DRUG	Rituximab	500mg,two times with two weeks interval

Timeline

• Start date: 2010-07-01
• Primary completion: 2011-09-01
• Completion: 2011-10-01
• First posted: 2012-05-08
• Last updated: 2012-05-08

Locations

1 site across 1 country: Iran